Photobiomodulation treatment for brain disorders: posttraumatic stress disorder (PTSD) and dementia

Lamartiniere, Randy; Bergeron, Rhett; Aung-Din, Ronald; Bennett, Matthew; Stephan, William; Banas, Louis J.

doi:10.1016/b978-0-12-815305-5.00042-7

Cited by 7 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mode of action of PBM treatment in PD merits further research. Transcranial PBM has recently been assessed for its effectiveness for a number of brainrelated conditions and injuries including stroke [79], traumatic brain injury [55], post-traumatic stress disorder [80], depression [81] and Alzheimer's disease [59]. Transcranial devices have been shown to modulate neural oscillations [82,83].…”

Section: Discussionmentioning

confidence: 99%

Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study

Liebert

Bicknell²,

Laakso

et al. 2021

BMC Neurol

View full text Add to dashboard Cite

Background Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons. Objective To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT). Methods Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%. Results Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed. Conclusions PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted. Trial registration Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p, registered on 12/01/2018.

show abstract

Section: Discussionmentioning

confidence: 99%

Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study

Liebert

Bicknell²,

Laakso

et al. 2021

BMC Neurol

View full text Add to dashboard Cite

show abstract

“…Lamartiniere et al [7] observed the significant improvement in cognition and personality in patients with vascular dementia, post-traumatic brain injury, and PTSD following PBMt. Over 60 patients treated at various clinical practices reported significant improvement in their condition after an average of four treatment sessions over an 8-day period.…”

Section: Ptsd Related Clinical Trialsmentioning

confidence: 99%

Most frequently used red and near infrared photobiomodulation therapy treatment parameters on the patients with post-traumatic stress disorder

Lim

2024

Mechanisms of Photobiomodulation Therapy XVIII

View full text Add to dashboard Cite

Photobiomodulation therapy (PBMt) has been reported effective for the treatment of post-traumatic stress disorder (PTSD) at low cost in the clinical trial journals for years. PBMt is reported to increase the production of brain-derived neurotrophic factor (BDNF) which promotes the growth and survival of neurons. BDNF is thought to play a role in the regulation of mood, learning, and memory, and it is also thought to be involved in the treatment of PTSD. PBMt is also reported to reduce inflammation in the brain, which is regarded helpful for reducing the symptoms of the psychiatric disorders, including PTSD. In this paper, the PBMt treatment recipes and the results on the PTSDs from the clinical papers already published are analyzed and compared. The most frequently used treatment parameters such as irradiances, wavelengths, doses, and light pulsing frequencies are derived. The treatment recipes for PTSD patients are also suggested.

show abstract

“…Our most recent papers described the clinical improvement in patients treated with our laser system for Post-traumatic Stress Disorder (PTSD) as well as for mild dementia [15] [16]. We have also recently obtained positive results in a case study of children and adults with attention deficit hyperactivity disorder (ADHD) [17].…”

Section: Introductionmentioning

confidence: 99%

Treatment Efficacy of Photobiomodulation for Moderate and Advanced Dementia or Alzheimer’s Disease: Case Studies

Stephan¹,

Banas²,

Hamblin³

2022

AAD

Self Cite

View full text Add to dashboard Cite

Extensive research is ongoing in the use of Photobiomodulation (PBM, often referred to as low-level or cold laser therapy) to treat Alzheimer's disease as well as other debilitating diseases. The following case studies further confirm that PBM could be a breakthrough approach to limit the progression of insidious diseases. We present four cases, two with mild to moderate dementia and two with more advanced symptoms. Several publications have shown beneficial results, however, several weeks of daily treatments were necessary. The cases described here suggest that moderate and advanced dementia cases can be significantly improved with three or four eight-minute treatments over a 5 -7-day period when using super-pulsing technology on Monday-Wednesday-Friday schedule (Figure 1). Gives a brief visual explanation of super-pulsing versus continuous wave technology.

show abstract

Photobiomodulation treatment for brain disorders: posttraumatic stress disorder (PTSD) and dementia

Cited by 7 publications

References 4 publications

Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study

Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study

Most frequently used red and near infrared photobiomodulation therapy treatment parameters on the patients with post-traumatic stress disorder

Treatment Efficacy of Photobiomodulation for Moderate and Advanced Dementia or Alzheimer’s Disease: Case Studies

Contact Info

Product

Resources

About